Kolon’s Invossa-K Phase 3 clinical trial to continue after FDA nod
Category: #health  By Saipriya Iyer  Date: 2020-04-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Kolon’s Invossa-K Phase 3 clinical trial to continue after FDA nod

Kolon Life Science has announced that it has received an approval to continue Invossa-K’s phase-3 clinical trial by the U.S. Food and Drug Administration. Invossa-K is a gene therapy for osteoarthritis and the trial is being run in the United States. 

Apparently, the FDA gave its approval for the drug test nearly a year after it had suspended the study. The Korean regulator had revoked the Invossa license on account of an ingredient mislabeling. The latest decision made by the FDA has given Kolon a fresh start concerning the Invossa business.

The FDA had sent an official notice to a Kolon Life Science subsidiary, Kolon TissueGene, that it will be removing the clinical hold on the Invossa’s phase 3 trial. As per the Kolon TissueGene, the FDA stated that the issues regarding the clinical hold had been resolved and the firm will be able to continue with the Invossa clinical trial.

Kolon had initiated Invossa’s phase-3 study on October 30 in 2018 in the U.S., which was later suspended by the FDA in 2019. The firm had admitted that the cell ingredient that came from the second fluid of the drug had not been derived from the cartilage but the kidney, which is also called GP2-293. The company had submitted the extra data twice for clearance from the regulatory body.

According to sources familiar with the matter, the FDA had requested the firm to submit supplementary materials that also include the ingredients of Invossa like the evaluation of the cell’s identity covering the way the drug composition has changed and the forthcoming measures. The regulator had demanded for analysis of the properties of Invossa ingredients.

The FDA has asked the firm to submit data placed on the stability of all the clinical samples as well as the improvement measures for the production process of Invossa.

 

Source credit- http://www.koreabiomed.com/news/articleView.html?idxno=7986



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

EU starts mass COVID-19 vaccination program in 27 member-states
EU starts mass COVID-19 vaccination program in 27 member-states
By Saipriya Iyer

The European Union has recently started a mass COVID-19 vaccination campaign to inoculate over 450 million individuals in 27 member-states.

EU leaders have reportedly negotiated var...

Asus announces plans to strengthen its offline retail presence in India
Asus announces plans to strengthen its offline retail presence in India
By Saipriya Iyer

AsusTek Computer Inc., popularly known as Asus, has reportedly announced plans to strengthen its offline retail presence across India. The firm, which had 7.5% of total market share in the Indian PC segment in the Q3 o...

Need for efficient sea vessels to augment marine turbocharger deployment
Need for efficient sea vessels to augment marine turbocharger deployment
By Saipriya Iyer

Increasing globalization and the subsequent rise in seaborne trade activities are fueling the global marine turbochargers industry size. These trends have created a significant demand for commercial vessels. Growth of ...